Présentations scientifiques

15

Juin 2026
12:30 E.S.T.

Safety and Efficacy of UCART22 in Heavily Pretreated Patients with Relapsed or Refractory CD22+ B-Cell Acute Lymphoblastic Leukemia (B-ALL): Results from the Phase 1 BALLI-01 Trial – Présentation orale – EHA 2026

Télécharger le PDF

13

Juin 2026
22:45 E.S.T.

Alemtuzumab exposure and sustained IL-2 drive UCART20x22 expansion and clinical response in adults with relapsed or refractory B-cell non-Hodgkin lymphoma: NATHALI-01 study – Présentation poster – EHA 2026

Télécharger le PDF

14

Mai 2026
06:26 E.S.T.

TALE-based epigenetic modulators show sustained knock-down of target genes in T-cells and HEPG2 via a high-throughput multiplex screening platform – Présentation poster – ASGCT 2026

Télécharger le PDF

8

Déc 2025
06:30 E.S.T.

Trial In Progress: Open-Label Dose-Finding and Dose-Expansion Study to Evaluate the Safety, Expansion, Persistence, and Clinical Activity of UCART20x22 in Subjects with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (B-NHL) NatHali-01_ASH 2025

Télécharger le PDF

8

Déc 2025
06:30 E.S.T.

Increased Alemtuzumab Exposure Correlates with Improved Responses in Heavily Pretreated r/r ALL patients: analysis of the BALLI-01 trial – ASH 2025

Télécharger le PDF

7

Oct 2025
06:40 E.S.T.

Circularization of Single-Stranded DNA Donor Template Unleashes the Power of Non-Viral Gene Delivery for Long-Term HSCs editing – ESGCT 2025

Télécharger le PDF

7

Oct 2025
06:40 E.S.T.

Comprehensive Analysis of TALEB Off-target Editing – ESGCT 2025

Télécharger le PDF

13

Mai 2025
12:25 E.S.T.

High-fidelity C-to-T editing with TALE base editors – ASGCT 2025

Télécharger le PDF

13

Mai 2025
08:18 E.S.T.

TALEN®- Mediated non-viral Transgene Insertion for the Advancement of Cellular and Gene Therapies – ASGCT 2025

Télécharger le PDF

24

Fév 2025
12:30 E.S.T.

CAR induced expression of synthetically engineered FAP-IL2v immunocytokine boosts persistent anti-tumor activity of TALEN®-edited allogeneic CAR T-cells without associated IL-2 toxicity

Télécharger le PDF

Présentations scientifiques

Safety and Efficacy of UCART22 in Heavily Pretreated Patients with Relapsed or Refractory CD22+ B-Cell Acute Lymphoblastic Leukemia (B-ALL): Results from the Phase 1 BALLI-01 Trial – Présentation orale – EHA 2026

Alemtuzumab exposure and sustained IL-2 drive UCART20x22 expansion and clinical response in adults with relapsed or refractory B-cell non-Hodgkin lymphoma: NATHALI-01 study – Présentation poster – EHA 2026

TALE-based epigenetic modulators show sustained knock-down of target genes in T-cells and HEPG2 via a high-throughput multiplex screening platform – Présentation poster – ASGCT 2026

Trial In Progress: Open-Label Dose-Finding and Dose-Expansion Study to Evaluate the Safety, Expansion, Persistence, and Clinical Activity of UCART20x22 in Subjects with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (B-NHL) NatHali-01_ASH 2025

Increased Alemtuzumab Exposure Correlates with Improved Responses in Heavily Pretreated r/r ALL patients: analysis of the BALLI-01 trial – ASH 2025

Circularization of Single-Stranded DNA Donor Template Unleashes the Power of Non-Viral Gene Delivery for Long-Term HSCs editing – ESGCT 2025

Comprehensive Analysis of TALEB Off-target Editing – ESGCT 2025

High-fidelity C-to-T editing with TALE base editors – ASGCT 2025

TALEN®- Mediated non-viral Transgene Insertion for the Advancement of Cellular and Gene Therapies – ASGCT 2025

CAR induced expression of synthetically engineered FAP-IL2v immunocytokine ​boosts persistent anti-tumor activity of TALEN®-edited allogeneic CAR T-cells without associated IL-2 toxicity

Scientific publications

CAR induced expression of synthetically engineered FAP-IL2v immunocytokine boosts persistent anti-tumor activity of TALEN®-edited allogeneic CAR T-cells without associated IL-2 toxicity